FIELD: biotechnology.
SUBSTANCE: invention relates to the induction of immunological tolerance, and can be used in medicine to induce antigen-specific tolerance in a subject in need. The following is proveded: a tolerogenic particle containing one or more encapsulated antigens selected from an autoimmune antigen, an enzyme for enzyme replacement therapy, or an allergen. The particle has a negative zeta potential of -80 mV to -30 mV, a diameter of 200 to 2,000 nanometers and contains polylactic acid (PLA), polyglycolic acid (PGA), lactide-glycolide copolymer (PLG) or liposome.
EFFECT: proposed particles are capable of inducing immunological tolerance to antigens they contain.
13 cl, 43 dwg, 24 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANTI-PRE-S1 HBV ANTIBODIES | 2016 |
|
RU2739955C2 |
| ANTIBODIES BINDING CTLA-4 AND APPLICATION THEREOF | 2018 |
|
RU2756100C1 |
| METHOD FOR ASSESSING NORMAL STATE OF IMMUNE REPERTOIRE AND ITS APPLICATION | 2016 |
|
RU2766004C1 |
| ANTIBODIES BINDING CD3 | 2017 |
|
RU2779489C2 |
| SPECIFIC ANTIBODIES TO PD-L1 AND METHODS FOR THEIR APPLICATION | 2017 |
|
RU2749109C2 |
| GENETIC STRUCTURE FOR USE IN THE TREATMENT OF NEURODEGENERATIVE DISORDER OR STROKE | 2018 |
|
RU2757932C2 |
| HPV-SPECIFIC BINDING MOLECULES | 2018 |
|
RU2804664C2 |
| METHOD FOR PREVENTION AND TREATMENT OF CANCER METASTASES AND BONE LOSS CAUSED BY CANCER METASTASES | 2007 |
|
RU2470665C2 |
| NEOANTIGENS AND THEIR USE | 2019 |
|
RU2813924C2 |
| ANTIBODIES TO TAU AND THEIR USE | 2018 |
|
RU2787779C2 |
